Ceramidase

Ceramidases are a group of enzymes that catalyze the hydrolysis of ceramide, dihydroceramide, and phytoceramide into sphingosine (SPH), dihydrosphingosine (DHS), and phytosphingosine (PHS), respectively, along with a free fatty acid. Ceramide catabolism is controlled by ceramidases that are pivotal in the pathophysiology of these diseases of altered lipid homeostasis such as Alzheimer’s disease, type 2 diabetes-induced insulin resistance, cancer, and cardiovascular diseases. Ceramidases are classified into the acid, neutral, and alkaline ceramidase subtypes according to the pH optima for their catalytic activity.

Ceramidase Related Products (24):

By Effects:	Inhibitors (19) Agonist (1)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-B0182

Carmofur	Inhibitor	99.95%
Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC₅₀ of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI).

HY-141866

Acid Ceramidase-IN-1		99.36%
Acid Ceramidase-IN-1 is a potent and oral bioavailable acid ceramidase (AC, ASAH-1) inhibitor (hAC IC₅₀=0.166 μM). Acid Ceramidase-IN-1 has excellent brain penetration in mice.

HY-103592

ARN14974	Inhibitor	99.29%
ARN14974, a benzoxazolone carboxamide, is a potent and systemically active inhibitors of intracellular acid ceramidase (IC₅₀=79 nM).

HY-145339

ARN19702	Inhibitor	99.80%
ARN19702 is a selective, orally active, reversible, and brain-penetrant N-acylethanolamine acid amidase (NAAA) inhibitor with an IC₅₀ of 230 nM for human NAAA. ARN19702 has pain relief effects.

HY-120813

ARN 077	Inhibitor	98.83%
ARN 077 is a potent and selective N-acylethanolamine acid amidase (NAAA) inhibitor with an IC₅₀ of 7 nM for human NAAA. ARN 077 significantly increases palmitoyl ethanolamine (PEA) levels within the CNS and has broad antinociceptive activity in mice and rats.

HY-139062

C6 Urea Ceramide	Inhibitor
C6 Urea Ceramide (Cer(d18:1/6:0) Urea) is an inhibitor of neutral ceramidase. C6 Urea Ceramide increases total ceramide levels in wild-type mouse embryonic fibroblasts (MEFs) and HT-29 colon cancer cells. C6 Urea Ceramide (5-10 μM) inhibits proliferation of HT-29 cells and induces apoptosis and autophagy, but is not toxic to non-cancerous cells. C6 Urea Ceramide decreases total and phosphorylated β-catenin levels in HT-29 and HCT116 cells, and induces colocalization of β-catenin with the 20S proteasome. C6 Urea Ceramide (1.25, 2.5, and 5 mg/kg) reduced tumor growth and increased C16, C18, C20, and C24 ceramide levels in tumor tissues in the HT-29 mouse xenograft model.

HY-169834

NAAA-IN-6	Inhibitor
NAAA-IN-6 (Example 43) is a NAAA inhibitor with IC₅₀ values between 0.01-0.1 µM, which can be used in cancer research.

HY-171003

SOBRAC	Inhibitor
SOBRAC is an irreversible inhibitor of acid ceramidase (Ceramidase) with a K_i of 29.7 nM, and it's also a derivative of the acid ceramidase inhibitor SABRAC (HY-165070).

HY-125351

SPT-IN-1	Inhibitor	99.18%
SPT-IN-1 (compound 1) is an orally active and potent SPT (serine palmitoyl transferase) inhibitor, with an IC₅₀ of 5.19 nM for hSPT1. SPT-IN-1 can be used for type 2 diabetes and dyslipidemia research.

HY-103359

Ceranib1		99.38%
Ceranib1 is a ceramidase inhibitor. Ceranib1 inhibits ceramidase activity toward an exogenous ceramide analog, induces the accumulation of multiple ceramide species, decreases levels of sphingosine and S1P. Ceranib1 inhibits the proliferation of ovarian cancer cells.

HY-147773

NAAA-IN-1	Inhibitor	99.65%
NAAA-IN-1 (Compound 1) is a potent and selective inhibitor of NAAA with an IC₅₀ of 7 nM. NAAA is a cysteine amidase which preferentially hydrolyzes the endogenous biolipids palmitoylethanolamide (PEA) and oleoylethanolamide (OEA). NAAA-IN-1 has the potential for the research of inflammation and pain.

HY-124597

ARN726	Inhibitor
ARN726 is a potent NAAA (N-acylethanolamine acid amidase) inhibitor with an IC₅₀ of 0.073 µM. ARN726 decreases alcohol self-administration in a dose-dependent manner.

HY-153396

Acid Ceramidase-IN-2	Inhibitor	≥99.0%
Acid Ceramidase-IN-2 (compound 1) is an acid ceramidase inhibitor with potentially antiproliferative and cytostatic activities. Moreover, human acid ceramidase is overexpressed in prostate cancer cells, indicating potential anti-tumor effect of Acid Ceramidase-IN-2. And Acid Ceramidase-IN-2 hydrolysis can be inhibited by 3 a-ketoamides GT85, GT98 and GT99 inhibits in vitro.

HY-137422

D-erythro-MAPP		≥98.0%
D-erythro-MAPP (D-e-MAPP) is a ceramidase inhibitor, with an IC₅₀ of 1-5 μM in vitro.

HY-132882

ARN19689	Inhibitor
ARN19689 is a potent, selective, orally active and non-covalent inhibitor of N?Acylethanolamine-Hydrolyzing Acid Amidase (NAAA), with an IC₅₀ of 42 nM. ARN19689 is a promising pharmacological tool to be further investigated in the field of inflammatory conditions.

HY-157223

ARN16186	Inhibitor
ARN16186;ARN 16186;ARN-16186

HY-E70181

Galactosylceramidase
Galactosylceramidase involves in lysosomal catabollsm of galactosytceramide. Galactosylceramidase can be used in study Krabbe disease.

HY-121975

N-Cyclohexanecarbonylpentadecylamine	Inhibitor
N-Cyclohexanecarbonylpentadecylamine (Compound 1) is an inhibitor of N-Acylethanolamine hydrolyzing acid amidase (NAAA) with an IC₅₀ of 4.5 μM. N-Cyclohexanecarbonylpentadecylamine can be used in the research of inflammation and pain.

HY-158783

SACLAC	Inhibitor
SACLAC, a Ceramide analog, is a potent and covalent acid ceramidase (ASAH1; AC) inhibitor with a K_i of 97.1 nM. SACLAC effectively blocks AC activity and induces a decrease in sphingosine 1-phosphate (S1P) and total ceramide levels. SACLAC reduces the levels of splicing factor SF3B1 and alternative Mcl-1 mRNA splicing, increases pro-apoptotic Mcl-1S levels to induce apoptosis in acute myeloid leukemia (AML) cells. SACLAC reduces the leukemic burden in human AML xenograft mouse models.

HY-147775

NAAA-IN-3	Inhibitor
NAAA-IN-3 (Compound 17a) is a potent and selective inhibitor of NAAA with an IC₅₀ of 50 nM. NAAA is a cysteine amidase which preferentially hydrolyzes the endogenous biolipids palmitoylethanolamide (PEA) and oleoylethanolamide (OEA). NAAA-IN-3 has the potential for the research of inflammation and pain.

Name
Email *

	Sorry, but the email address you supplied was invalid.